A Medsky Topics feed composed of posts covering recent news related to GLP-1 Agonists such as Semaglutide (Ozempic, Wegovy, Rybelsus), Liraglutide (Victoza), and Tirzepatide (Zepbound, Mounjaro) Powered by @medsky.social
Feed on Bluesky
reut.rs
Lawsuits claiming Ozempic, other GLP-1s led to blindness become second mass litigation over the drugs
A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly alleging patients lost some or all of their eyesight while taking the companies' blockbuster weight loss drugs before a judge in Pennsylvania.
www.sciencenews.org
GLP-1 drugs failed to slow Alzheimerâs in two big clinical trials
Tantalizing results from small trials and anecdotes raised hopes that drugs like Ozempic could help. Despite setbacks, researchers arenât giving up yet.
www.dailymaverick.co.za
Ozempic, Wegovy and the R33bn bill that is SA's obesity time bomb | Daily Maverick
www.spotlightpa.org
Pennsylvania restricts Medicaid coverage for GLPâ1 drugs
Starting Jan.âŻ1, 2026, Pennsylvania will limit GLPâ1 weightâloss drugs under Medicaid â threatening access for thousands of lowâincome patients.
www.spotlightpa.org
Pennsylvania restricts Medicaid coverage for GLPâ1 drugs
Starting Jan.âŻ1, 2026, Pennsylvania will limit GLPâ1 weightâloss drugs under Medicaid â threatening access for thousands of lowâincome patients.
www.nature.com
Advances in incretin-based drug discovery in 2025
Nature Reviews Endocrinology, Published online: 12 December 2025; doi:10.1038/s41574-025-01219-4The efficacy of anti-obesity drugs that use glucagon-like peptide 1 receptor agonism and glucose-dependent insulinotropic polypeptide agonism raises critical questions about how next-generation drugs might offer increased metabolic benefits. In 2025, new research into incretin-based treatments has brought us closer to answering these questions.
www.thetimes.com
Criminals selling dangerous weight-loss jabs on social media and in gyms
Pharmaceutical bosses have issued a stark warning about medicines such as Mounjaro sold online without safety controls as gangs branch out from hard drugs
bit.ly
A salute to innovation: exenatide in diabetes and obesity drug development at Amylin Pharmaceuticals - Nature Metabolism
The glucagon-like peptide 1 receptor agonist (GLP-1RA) class of medicines has emerged as transformative for the treatment of diabetes, obesity and other diseases. On the twentieth anniversary of the approval of exenatide (Byetta), three former employees of Amylin Pharmaceuticals acknowledge the contributions of some of the individuals and the innovation responsible for delivering the first approved GLP-1RA â the forerunner to the modern blockbuster drugs.
reut.rs
Alzheimer's drug hunt learns from cancer fight's multi-target playbook
Alzheimer's trials testing Novo Nordiskâs blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to approaching the brain-wasting disease as a system of complex pathways, much the way the field of cancer therapeutics has been transformed in recent years.
sciencedirect.com
One small molecule for man, one giant leap for mankind with obesity
The ATTAIN-1 trial launches a new era in obesity care. Orforglipron, the first oral small-molecule GLP-1 receptor agonist to complete a phase 3 clinicâŚ
www.nature.com
Advances in incretin-based drug discovery in 2025
Nature Reviews Endocrinology, Published online: 12 December 2025; doi:10.1038/s41574-025-01219-4The efficacy of anti-obesity drugs that use glucagon-like peptide 1 receptor agonism and glucose-dependent insulinotropic polypeptide agonism raises critical questions about how next-generation drugs might offer increased metabolic benefits. In 2025, new research into incretin-based treatments has brought us closer to answering these questions.
dlvr.it
Bariatric Surgery May Outperform GLP-1 RAs in Longer-Term Weight Loss Benefits
In patients with obesity, a retrospective study found greater weight loss and lower costs over 2 years after metabolic bariatric surgery than with glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment.
reut.rs
Ozempic launches in India at $24 a week as Novo targets booming diabetes market
Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 per week and targeting a booming diabetes and obesity market expected to power industry growth this decade.
dlvr.it
GLP-1s may reduce risk for cataracts, dry AMD
GLP-1 receptor agonists are not associated with increased risks for dry age-related macular degeneration or cataract development, according to two recently published studies. The data instead showed significantly reduced risk for cataracts, as well as lower risk for dry AMD, linked with the use of GLP-1s, according to Abhimanyu Ahuja, MD, an ophthalmology resident at the Oregon Health & Science University Casey Eye Institute, and colleagues. âOther studies have demonstrated that these medications have anti-inflammatory and neuroprotective properties,â Ahuja told Healio. âWe
www.nytimes.com
Major Weight Loss and Knee-Pain Relief Seen With New Eli Lilly Drug
dlvr.it
GLP-1s may reduce risk for cataracts, dry AMD
GLP-1 receptor agonists are not associated with increased risks for dry age-related macular degeneration or cataract development, according to two recently published studies. The data instead showed significantly reduced risk for cataracts, as well as lower risk for dry AMD, linked with the use of GLP-1s, according to Abhimanyu Ahuja, MD, an ophthalmology resident at the Oregon Health & Science University Casey Eye Institute, and colleagues. âOther studies have demonstrated that these medications have anti-inflammatory and neuroprotective properties,â Ahuja told Healio. âWe
nyti.ms
New Eli Lilly Drug Retatrutide Brought Major Weight Loss in Trial
The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.
www.medpagetoday.com
Bone Fractures Down With GLP-1 Drugs in the Picture
Cohort study suggests bone health may be the next benefit linked to the popular medications
Medsky Topics 